Post kala-azar dermal leishmaniasis burden at the village level in selected high visceral leishmaniasis endemic upazilas in Bangladesh

被引:0
|
作者
Ghosh, Debashis [1 ]
Sagar, Soumik Kha [1 ]
Uddin, Md Rasel [1 ]
Rashid, Md Utba [1 ,2 ]
Maruf, Shomik [1 ]
Nath, Rupen [1 ]
Islam, Md Nazmul [3 ]
Aktaruzzaman, M. M. [3 ]
Sohel, Abu Nayeem Mohammad [3 ]
Banjara, Megha Raj [4 ,5 ]
Kroeger, Axel [6 ]
Aseffa, Abraham [4 ]
Mondal, Dinesh [1 ]
机构
[1] Int Ctr Diarrhoeal Dis Res, Nutr Res Div NRD, Bangladesh ICDDR B, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh
[2] Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC USA
[3] Directorate Gen Hlth Serv DGHS, Communicable Dis Control CDC, Dhaka, Bangladesh
[4] WHO, UNICEF UNDP World Bank World Hlth Org Special Prog, Geneva, Switzerland
[5] Tribhuvan Univ, Cent Dept Microbiol, Kathmandu, Nepal
[6] Univ Med Ctr, Inst Infect Prevent, Ctr Med & Soc, Freiburg, Germany
关键词
Post kala-azar dermal leishmaniasis; Prevalence; Knowledge; Stigma; Bangladesh; EPIDEMIOLOGY;
D O I
10.1016/j.ijid.2024.107213
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: As post kala-azar Dermal Leishmaniasis (PKDL) threatens the success of the Visceral Leishmaniasis (VL) elimination initiative, we aimed to investigate the PKDL burden, including an active search for PKDL in leprosy-negative skin lesion cases. We also investigated their health-seeking behavior and perceived level of stigma. Methods: This was a cross-sectional survey among inhabitants in the VL-endemic villages of the five most VL-endemic upazilas. VL experts trained medical officers in Upazila Health Complexes (UHCs) and leprosy facilities in PKDL management. Frontline workers conducted house-to-house surveys, referring PKDL suspects to designated centers. Data analysis involved Epi Info version 7 and IBM SPSS Statistics 25. Results: Among 472,435 screened individuals, 4022 had past VL (0.85 %). Among the screened population, 82 were PKDL suspects, and 62 PKDL cases were confirmed. The overall PKDL burden was 1.3 (95 % CI: 1.0-1.7) in the 10,000 population in the endemic villages. Male predominance and macular form of PKDL were observed. Thirty-nine PKDL patients perceived stigma of different levels. Only 27 of 62 (44 %) had received PKDL treatment. Medicine's unavailability and side effects were a major reason behind treatment interruption. Active screening among 137 leprosy-negative PKDL suspects yielded 10 (7.3 %) PKDL cases. Conclusion: The existence of PKDL cases in the VL endemic areas is a concern as those are inter-epidemic reservoirs. As per the WHO roadmap, the PKDL burden must be reduced by 70 % and 100 %, respectively, by 2026 and 2030. NKEP can take the current burden of 1.3 per 10,000 people in VL endemic villages as a baseline. Integrating active case detection for PKDL in leprosy hospitals and screening centers is feasible and worth deploying nationwide. (c) 2024 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY IGO license ( http://creativecommons.org/licenses/by/3.0/igo/ )
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile
    Ismail, A
    El Hassan, AM
    Kemp, K
    Gasim, S
    Kadaru, AEMY
    Moller, T
    Kharazmi, A
    Theander, TG
    JOURNAL OF PATHOLOGY, 1999, 189 (04) : 615 - 622
  • [42] Feasibility of a combined camp approach for vector control together with active case detection of visceral leishmaniasis, post kala-azar dermal leishmaniasis, tuberculosis, leprosy and malaria in Bangladesh, India and Nepal: an exploratory study
    Banjara, Megha R.
    Kroeger, Axel
    Huda, Mamun M.
    Kumar, Vijay
    Gurung, Chitra K.
    Das, Murari L.
    Rijal, Suman
    Das, Pradeep
    Mondal, Dinesh
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2015, 109 (06) : 408 - 415
  • [43] Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India
    Raju, B. V. Subba
    Gurumurthy, Srividya
    Kuhls, Katrin
    Bhandari, Vasundhra
    Schnonian, Gabriele
    Salotra, Poonam
    PARASITOLOGY RESEARCH, 2012, 111 (04) : 1559 - 1568
  • [44] Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis
    Kennedy, Grace C.
    O'Brien, Katherine
    Nyakundi, Hellen
    Kitondo, Mwatela
    Biwott, Wilson
    Wamai, Richard G.
    PLOS ONE, 2024, 19 (06):
  • [45] Atypical Post Kala Azar Dermal Leishmaniasis with "Muzzle Area'' Swelling
    Arora, Sandeep
    Bal, Arvinder Singh
    Baveja, Sukriti
    Sood, Aradhana
    Rathi, Khushi Ram
    Patil, Pradeep
    INDIAN JOURNAL OF DERMATOLOGY, 2015, 60 (01) : 88 - 90
  • [46] Short communication: Post-kala-azar dermal leishmaniasis - an appraisal
    Ramesh, V.
    Singh, Ruchi
    Salotra, Poonam
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2007, 12 (07) : 848 - 851
  • [47] Increasing Incidence of Post-Kala-Azar Dermal Leishmaniasis in a Population-Based Study in Bangladesh
    Rahman, Kazi Mizanur
    Islam, Shamim
    Rahman, Muhammad Waliur
    Kenah, Eben
    Galive, Chowdhury Mohammad
    Zahid, M. M.
    Maguire, James
    Rahman, Mahmudur
    Haque, Rashidul
    Luby, Stephen P.
    Bern, Caryn
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (01) : 73 - 76
  • [48] Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis
    Khalil, EAG
    Nur, NM
    Zijlstra, EE
    ElHassan, AM
    Davidson, RN
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1996, 90 (02) : 187 - 188
  • [49] Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study
    Das, Sushmita
    Mandal, Rakesh
    Rabidas, Vidya Nand
    Verma, Neena
    Pandey, Krishna
    Ghosh, Ashok Kumar
    Kesari, Sreekant
    Kumar, Ashish
    Purkait, Bidyut
    Lal, Chandra Sekhar
    Das, Pradeep
    PLOS NEGLECTED TROPICAL DISEASES, 2016, 10 (10):
  • [50] Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis
    Ramesh, V
    Dixit, Keerti Kaumudee
    Sharma, Neha
    Singh, Ruchi
    Salotra, Poonam
    JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (04) : 608 - 617